Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 787
Rating:

Dr Teresa Macarulla - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain

Dr Teresa Macarulla talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the phase III POLO trial - which assessed the use of olaparib as a maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA1/2 mutation and metastatic pancreatic cancer, compared with a placebo.

Dr Macarulla mentions that progression-free survival was the primary endpoint of this trial, along with overall survival, response rate, quality of life and adverse events were also assessed.

She emphasises the importance of this trial, which is the first positive study in this setting and offers a novel treatment option with patients with metastatic pancreatic cancer.

Dr Macarulla also believes patients should be tested routinely for BRCA1/2 mutations, to identify the 7-8% of patients that could benefit from this treatment.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation